Advertisement

Secondary Prevention of Heart Disease in Women: Gaps in Care/Gaps in Knowledge—Where Do We Need to Focus Our Attention

  • Emily Lau
  • JoAnne M. FoodyEmail author
Women + Heart Disease (E Jackson, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Women and Heart Disease

Abstract

Cardiovascular disease (CVD) is the leading cause of death in women in the USA, and yet, CVD is consistently underestimated and undertreated in women. Awareness of this gender gap is growing, but still persists. Women with existing CVD are a particularly vulnerable and neglected population. Better understanding of the secondary prevention of CVD is sorely needed. Women are underrepresented in all CVD trials and sex-specific research is lacking. Consequently, the present guidelines for the secondary prevention of CVD in women are largely derived from studies performed in men. Albeit imperfect, these guidelines are less frequently applied to female patients. CVD outcomes are consistently worse in women than men, highlighting the need to address this gender disparity. We review the current guidelines and data on the secondary prevention of CVD in women and outline areas in need of further investigation and intervention.

Keywords

Secondary prevention Cardiovascular disease Coronary artery disease Women 

Notes

Compliance with Ethics Guidelines

Conflict of Interest

Joanne Foody and Emily Lau have no relevant disclosures to report.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by the author.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.•
    Mosca L, Barrett-Connor E, Wenger NK. Sex/gender differences in cardiovascular disease prevention: what a difference a decade makes. Circulation. 2011;124(19):2145–54. This review presents sex/gender differences in the burden of CVD and explores how clinical trials can be used to provide recommendations for CVD prevention in women. CrossRefPubMedCentralPubMedGoogle Scholar
  2. 2.
    Vaccarino V, Parsons L, Every NR, Barron HV, Krumholz HM. Sex-based differences in early mortality after myocardial infarction. National Registry of Myocardial Infarction 2 Participants. N Engl J Med. 1999;341(4):217–25.CrossRefPubMedGoogle Scholar
  3. 3.
    Mulcahy R, Hickey N, Maurer B. Coronary heart disease in women. Study of risk factors in 100 patients less than 60 years of age. Circulation. 1967;36(4):577–86.CrossRefPubMedGoogle Scholar
  4. 4.••
    Gulati M, Shaw LJ, Bairey Merz CN. Myocardial ischemia in women: lessons from the NHLBI WISE study. Clin Cardiol. 2012;35(3):141–8. This review highlights the major findings from the WISE study which introduced the idea of a “female” pattern of ischemic heart disease. Although women are more likely to experience myocardial ischemia and death, they have less obstructive coronary disease.CrossRefPubMedCentralPubMedGoogle Scholar
  5. 5.•
    Clayton JA, Collins FS. Policy: NIH to balance sex in cell and animal studies. Nature. 2014;509(7500):282–3. This policy statement announces that NIH is dedicated to ensuring that sex is balanced in all funded preclinical research. CrossRefPubMedGoogle Scholar
  6. 6.•
    Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S1–45. The American College of Cardiology/American Heart Association task force presents guidelines for the management of hyperlipidemia for primary and secondary prevention of CVD in adult patients. CrossRefPubMedGoogle Scholar
  7. 7.•
    Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-Jones DM, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women—2011 update: a guideline from the American Heart Association. Circulation. 2011;123(11):1243–62. The American Heart Association task force presents evidence-based guidelines for the primary and secondary prevention of CVD in women. CrossRefPubMedCentralPubMedGoogle Scholar
  8. 8.
    Kritchevsky D. Dietary protein, cholesterol and atherosclerosis: a review of the early history. J Nutr. 1995;125(3 Suppl):589s–93.PubMedGoogle Scholar
  9. 9.
    Bowen DJ, Henderson MM, Iverson D, Burrows E, Henry H, Foreyt J. Reducing dietary fat: understanding the success of the women’s health trial. Cancer Prev Int. 1994;1(1):21–30.CrossRefGoogle Scholar
  10. 10.
    Krummel DA, Koffman DM, Bronner Y, Davis J, Greenlund K, Tessaro I, et al. Cardiovascular health interventions in women: what works? J Womens Health Gend Based Med. 2001;10(2):117–36.CrossRefPubMedGoogle Scholar
  11. 11.
    Zhang Y. Cardiovascular diseases in American women. Nutr Metab Cardiovasc Dis NMCD. 2010;20(6):386–93.CrossRefGoogle Scholar
  12. 12.
    Owens JF, Matthews KA, Wing RR, Kuller LH. Physical activity and cardiovascular risk: a cross-sectional study of middle-aged premenopausal women. Prev Med. 1990;19(2):147–57.CrossRefPubMedGoogle Scholar
  13. 13.
    Nies MA, Vollman M, Cook T. African-American women’s experiences with physical activity in their daily lives. Public Health Nurs (Boston, Mass). 1999;16(1):23–31.CrossRefGoogle Scholar
  14. 14.
    Banks-Wallace J, Conn V. Interventions to promote physical activity among African American women. Public Health Nurs (Boston, Mass). 2002;19(5):321–35.CrossRefGoogle Scholar
  15. 15.
    Agaku IT, King BA, Dube SR. Current cigarette smoking among adults—United States, 2005–2012. MMWR Morb Mortal Wkly Rep. 2014;63(2):29–34.PubMedGoogle Scholar
  16. 16.
    Mackay J, Amos A. Women and tobacco. Respirology (Carlton, Vic). 2003;8(2):123–30.CrossRefGoogle Scholar
  17. 17.
    Melloni C, Berger JS, Wang TY, Gunes F, Stebbins A, Pieper KS, et al. Representation of women in randomized clinical trials of cardiovascular disease prevention. Circ Cardiovasc Qual Outcomes. 2010;3(2):135–42.CrossRefPubMedGoogle Scholar
  18. 18.
    Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study. Ann Intern Med. 1971;74(1):1–12.CrossRefPubMedGoogle Scholar
  19. 19.
    Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol. 1998;81(4a):7b–12.CrossRefPubMedGoogle Scholar
  20. 20.
    Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. The New England Journal of Medicine 2010; 362(17):1563–74.Google Scholar
  21. 21.
    Howard BV, Cowan LD, Go O, Welty TK, Robbins DC, Lee ET. Adverse effects of diabetes on multiple cardiovascular disease risk factors in women. The strong heart study. Diabetes Care. 1998;21(8):1258–65.CrossRefPubMedGoogle Scholar
  22. 22.
    Koerbel G, Korytkowski M. Coronary heart disease in women with diabetes. Diabetes Spectr. 2003;16(3):148–53.CrossRefGoogle Scholar
  23. 23.
    Hu FB, Stampfer MJ, Haffner SM, Solomon CG, Willett WC, Manson JE. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care. 2002;25(7):1129–34.CrossRefPubMedGoogle Scholar
  24. 24.
    Mente A, Yusuf S, Islam S, McQueen MJ, Tanomsup S, Onen CL, et al. Metabolic syndrome and risk of acute myocardial infarction a case–control study of 26,903 subjects from 52 countries. J Am Coll Cardiol. 2010;55(21):2390–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Gitt A, Bramlage P, Towae F, Papp A, Deeg E, Senges J, Zeymer U, Zahn R, Fleischmann H, Boehler S, et al. Newly diagnosed diabetes and prediabetes in patients after acute myocardial infarction predicts adverse outcomes during a three-year follow-up: results of the sweetheart registry. J Am Coll Cardiol. 2013; 61(10_S).Google Scholar
  26. 26.•
    James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507–20. The Joint National Committee 8 presents their updated evidence based guidelines for the management of high blood pressure in adults. CrossRefPubMedGoogle Scholar
  27. 27.
    Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Heart disease and stroke statistics—2014 update: a report from the American Heart Association. Circulation. 2014;129(3):e28–292.CrossRefPubMedGoogle Scholar
  28. 28.
    Hertz RP, Unger AN, Cornell JA, Saunders E. Racial disparities in hypertension prevalence, awareness, and management. Arch Intern Med. 2005;165(18):2098–104.CrossRefPubMedGoogle Scholar
  29. 29.
    Pimenta E. Hypertension in women. Hypertens Res Off J Jpn Soc Hypertens. 2012;35(2):148–52.CrossRefGoogle Scholar
  30. 30.
    Hsia J, Margolis KL, Eaton CB, Wenger NK, Allison M, Wu L, et al. Prehypertension and cardiovascular disease risk in the women’s health initiative. Circulation. 2007;115(7):855–60.CrossRefPubMedGoogle Scholar
  31. 31.
    August P, Oparil S. Hypertension in women. J Clin Endocrinol Metab. 1999;84(6):1862–6.CrossRefPubMedGoogle Scholar
  32. 32.
    Os I, Oparil S, Gerdts E, Hoieggen A. Essential hypertension in women. Blood Press. 2004;13(5):272–8.CrossRefPubMedGoogle Scholar
  33. 33.
    Os I, Bratland B, Dahlof B, Gisholt K, Syvertsen JO, Tretli S. Female preponderance for lisinopril-induced cough in hypertension. Am J Hypertens. 1994;7(11):1012–5.PubMedGoogle Scholar
  34. 34.
    Neaton JD, Grimm Jr RH, Prineas RJ, Stamler J, Grandits GA, Elmer PJ, et al. Treatment of mild hypertension study. Final results. Treatment of mild hypertension study research group. JAMA. 1993;270(6):713–24.CrossRefPubMedGoogle Scholar
  35. 35.•
    Lichtman JH, Froelicher ES, Blumenthal JA, Carney RM, Doering LV, Frasure-Smith N, et al. Depression as a risk factor for poor prognosis among patients with acute coronary syndrome: systematic review and recommendations: a scientific statement from the American Heart Association. Circulation. 2014;129(12):1350–69. The American Heart Association recognizes depression as an independent risk factor for cardiovascular disease. CrossRefPubMedGoogle Scholar
  36. 36.
    Smith Jr SC, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011;124(22):2458–73.CrossRefPubMedGoogle Scholar
  37. 37.
    Nemeroff CB, Knight DL, Franks J, Craighead WE, Krishnan KR. Further studies on platelet serotonin transporter binding in depression. Am J Psychiatry. 1994;151(11):1623–5.CrossRefPubMedGoogle Scholar
  38. 38.
    Berkman LF, Blumenthal J, Burg M, Carney RM, Catellier D, Cowan MJ, et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) randomized trial. JAMA. 2003;289(23):3106–16.CrossRefPubMedGoogle Scholar
  39. 39.
    Huang CJ, Hsieh MH, Hou WH, Liu JC, Jeng C, Tsai PS. Depression, antidepressants, and the risk of coronary heart disease: a population-based cohort study. Int J Cardiol. 2013;168(5):4711–6.CrossRefPubMedGoogle Scholar
  40. 40.
    Kannel WB, Hjortland MC, McNamara PM, Gordon T. Menopause and risk of cardiovascular disease: the Framingham study. Ann Intern Med. 1976;85(4):447–52.CrossRefPubMedGoogle Scholar
  41. 41.
    Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999;340(23):1801–11.CrossRefPubMedGoogle Scholar
  42. 42.
    Vaidya D, Becker DM, Bittner V, Mathias RA, Ouyang P. Ageing, menopause, and ischaemic heart disease mortality in England, Wales, and the United States: modelling study of national mortality data. BMJ (Clin Res Ed). 2011;343:d5170.CrossRefGoogle Scholar
  43. 43.
    Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) research group. JAMA. 1998;280(7):605–13.CrossRefPubMedGoogle Scholar
  44. 44.
    Harman SM, Brinton EA, Cedars M, Lobo R, Manson JE, Merriam GR, et al. KEEPS: The kronos early estrogen prevention study. Climacteric J Int Menopause Soc. 2005;8(1):3–12.CrossRefGoogle Scholar
  45. 45.••
    Mosca L, Hammond G, Mochari-Greenberger H, Towfighi A, Albert MA. Fifteen-year trends in awareness of heart disease in women: results of a 2012 American Heart Association national survey. Circulation. 2013;127(11):1254–63. This study showed that awareness of heart disease in women has been growing over the last 15 years, but significant gaps still remain.CrossRefPubMedCentralPubMedGoogle Scholar
  46. 46.
    Mosca L, Ferris A, Fabunmi R, Robertson RM. Tracking women’s awareness of heart disease: an American Heart Association national study. Circulation. 2004;109(5):573–9.CrossRefPubMedGoogle Scholar
  47. 47.•
    Yancy CW, Wang TY, Ventura HO, Pina IL, Vijayaraghavan K, Ferdinand KC, et al. The coalition to reduce racial and ethnic disparities in cardiovascular disease outcomes (credo): why credo matters to cardiologists. J Am Coll Cardiol. 2011;57(3):245–52. This report outlines the mission and efforts of the American College of Cardiology's Coalition to Reduce Racial Ethnic Disparities in Cardiovascular Disease Outcomes (credo) to help improve delivery of care and heatlh outcomes of diverse patient populations. CrossRefPubMedGoogle Scholar
  48. 48.
    Freemantle N, Cleland J, Young P, Mason J, Harrison J. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ (Clin Res Ed). 1999;318(7200):1730–7.CrossRefGoogle Scholar
  49. 49.
    Cho L, Hoogwerf B, Huang J, Brennan DM, Hazen SL. Gender differences in utilization of effective cardiovascular secondary prevention: a Cleveland clinic prevention database study. J Womens Health (2002). 2008;17(4):515–21.CrossRefGoogle Scholar
  50. 50.
    Daly C, Clemens F, Lopez Sendon JL, Tavazzi L, Boersma E, Danchin N, et al. Gender differences in the management and clinical outcome of stable angina. Circulation. 2006;113(4):490–8.CrossRefPubMedGoogle Scholar
  51. 51.
    Butler J, Arbogast PG, BeLue R, Daugherty J, Jain MK, Ray WA, et al. Outpatient adherence to beta-blocker therapy after acute myocardial infarction. J Am Coll Cardiol. 2002;40(9):1589–95.CrossRefPubMedGoogle Scholar
  52. 52.
    Crane PB, Oles KS, Kennedy-Malone L. Beta-blocker medication usage in older women after myocardial infarction. J Am Acad Nurse Pract. 2006;18(10):463–70.CrossRefPubMedGoogle Scholar
  53. 53.
    Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N Engl J Med. 2000;342(3):145–53.CrossRefPubMedGoogle Scholar
  54. 54.
    Savarese G, Costanzo P, Cleland JG, Vassallo E, Ruggiero D, Rosano G, et al. A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure. J Am Coll Cardiol. 2013;61(2):131–42.CrossRefPubMedGoogle Scholar
  55. 55.
    Reibis RK, Bestehorn K, Pittrow D, Jannowitz C, Wegscheider K, Voller H. Elevated risk profile of women in secondary prevention of coronary artery disease: a 6-year survey of 117,913 patients. J Womens Health (2002). 2009;18(8):1123–31.CrossRefGoogle Scholar
  56. 56.
    Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors. Circulation. 1998;97(14):1411–20.CrossRefPubMedGoogle Scholar
  57. 57.
    Cooke CE, Fatodu H. Physician conformity and patient adherence to ACE inhibitors and ARBs in patients with diabetes, with and without renal disease and hypertension, in a medicaid managed care organization. J Manag Care Pharm JMCP. 2006;12(8):649–55.Google Scholar
  58. 58.
    The LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998; 339:1349–57.Google Scholar
  59. 59.
    Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360(9346):1623–30.CrossRefPubMedGoogle Scholar
  60. 60.
    Gutierrez J, Ramirez G, Rundek T, Sacco RL. Statin therapy in the prevention of recurrent cardiovascular events: a sex-based meta-analysis. Arch Intern Med. 2012;172(12):909–19.CrossRefPubMedGoogle Scholar
  61. 61.•
    Koopman C, Vaartjes I, Heintjes EM, Spiering W, van Dis I, Herings RM, et al. Persisting gender differences and attenuating age differences in cardiovascular drug use for prevention and treatment of coronary heart disease, 1998–2010. Eur Heart J. 2013;34(41):3198–205. This review outlines the age-specific and gender-specific trends in primary prevention, secondary prevention, and in-hospital treatment of coronary heart disase from 1998-2010. CrossRefPubMedGoogle Scholar
  62. 62.
    Arnold SV, Spertus JA, Tang F, Krumholz HM, Borden WB, Farmer SA, et al. Statin use in outpatients with obstructive coronary artery disease. Circulation. 2011;124(22):2405–10.CrossRefPubMedCentralPubMedGoogle Scholar
  63. 63.
    Golomb BA, Evans MA, Dimsdale JE, White HL. Effects of statins on energy and fatigue with exertion: results from a randomized controlled trial. Arch Intern Med. 2012;172(15):1180–2.CrossRefPubMedCentralPubMedGoogle Scholar
  64. 64.•
    Kostis WJ, Cheng JQ, Dobrzynski JM, Cabrera J, Kostis JB. Meta-analysis of statin effects in women versus men. J Am Coll Cardiol. 2012;59(6):572–82. This meta-analysis examines the sex-specific differences in efficacy and safety of statin therapy for the prevention and treatment of coronary heart disease. CrossRefPubMedGoogle Scholar
  65. 65.
    Johansen KL. Increased diabetes mellitus risk with statin use: comment on “statin use and risk of diabetes mellitus in postmenopausal women in the women’s health initiative”. Arch Intern Med. 2012;172(2):152.CrossRefPubMedGoogle Scholar
  66. 66.
    Undela K, Srikanth V, Bansal D. Statin use and risk of breast cancer: a meta-analysis of observational studies. Breast Cancer Res Treat. 2012;135(1):261–9.CrossRefPubMedGoogle Scholar
  67. 67.•
    Stein EA, Mellis S, Yancopoulos GD, Stahl N, Logan D, Smith WB, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med. 2012;366(12):1108–18. This study presents three phase I studies of a monoclonal antibody to PCSK9, a novel agent for the treatment of hyperlipidemia. CrossRefPubMedGoogle Scholar
  68. 68.•
    Stroes E, Colquhoun D, Sullivan D, Civeira F, Rosenson RS, Watts GF, et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol. 2014;63(23):2541–8. This study is a randomized controlled study that compares subcutaneous evoloumab, an anti-PCKS9 inhibitor, to oral ezetimibe in patients with hyperlipidema who were unable to tolerate effective statin doses. CrossRefPubMedGoogle Scholar
  69. 69.•
    Robinson JG, Nedergaard BS, Rogers WJ, Fialkow J, Neutel JM, Ramstad D, et al. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA. 2014;311(18):1870–82. This study presents a randomized controlled study that evalutes the efficcy and safety of evolocumab, an anti-PCSK9 antibody, when used with a moderate- or high-intensity statin for the treatment of hyperlipidemia. CrossRefPubMedGoogle Scholar
  70. 70.
    Mayne J, Raymond A, Chaplin A, Cousins M, Kaefer N, Gyamera-Acheampong C, et al. Plasma PCSK9 levels correlate with cholesterol in men but not in women. Biochem Biophys Res Commun. 2007;361(2):451–6.CrossRefPubMedGoogle Scholar
  71. 71.
    Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366(9500):1849–61.CrossRefPubMedGoogle Scholar
  72. 72.
    Ginsberg HN. The ACCORD (Action to Control Cardiovascular Risk in Diabetes) lipid trial: what we learn from subgroup analyses. Diabetes Care. 2011;34 Suppl 2:S107–8.CrossRefPubMedCentralPubMedGoogle Scholar
  73. 73.
    Keene D, Price C, Shun-Shin MJ, Francis DP. Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients. BMJ (Clin Res Ed). 2014;349:g4379.Google Scholar
  74. 74.
    Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357(21):2109–22.CrossRefPubMedGoogle Scholar
  75. 75.
    Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med. 2007;356(13):1304–16.CrossRefPubMedGoogle Scholar
  76. 76.
    Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367(22):2089–99.CrossRefPubMedGoogle Scholar
  77. 77.
    Luscher TF, Taddei S, Kaski JC, Jukema JW, Kallend D, Munzel T, et al. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial. Eur Heart J. 2012;33(7):857–65.CrossRefPubMedCentralPubMedGoogle Scholar
  78. 78.
    Gotto Jr AM, Cannon CP, Li XS, Vaidya S, Kher U, Brinton EA, et al. Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease. Am J Cardiol. 2014;113(1):76–83.CrossRefPubMedGoogle Scholar
  79. 79.
    Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324:71–86.Google Scholar
  80. 80.•
    Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849–60. This meta-analysis examined the use of aspirin for primary prevention of myocardial infarction (MI), stroke, or vascular death. CrossRefPubMedGoogle Scholar
  81. 81.•
    Becker DM, Segal J, Vaidya D, Yanek LR, Herrera-Galeano JE, Bray PF, et al. Sex differences in platelet reactivity and response to low-dose aspirin therapy. JAMA. 2006;295(12):1420–7. This meta-analysis examines the serious vascular events and major bleeds in long-term aspirin use versus control. CrossRefPubMedGoogle Scholar
  82. 82.
    Sam C, Massaro JM, D’Agostino Sr RB, Levy D, Lambert JW, Wolf PA, et al. Warfarin and aspirin use and the predictors of major bleeding complications in atrial fibrillation (the Framingham Heart Study). Am J Cardiol. 2004;94(7):947–51.CrossRefPubMedGoogle Scholar
  83. 83.
    Marrugat J, Sala J, Masia R, Pavesi M, Sanz G, Valle V, et al. Mortality differences between men and women following first myocardial infarction. RESCATE Investigators. Recursos Empleados en el Sindrome Coronario Agudo y Tiempo de Espera. JAMA. 1998;280(16):1405–9.CrossRefPubMedGoogle Scholar
  84. 84.•
    Rivera CM, Song J, Copeland L, Buirge C, Ory M, McNeal CJ. Underuse of aspirin for primary and secondary prevention of cardiovascular disease events in women. J Womens Health (2002). 2012;21(4):379–87. This study evaluates self-reported aspirin use in women for primary and secondary prevention of CVD from 2004 to 2009. CrossRefGoogle Scholar
  85. 85.
    Maree AO, Fitzgerald DJ. Variable platelet response to aspirin and clopidogrel in atherothrombotic disease. Circulation. 2007;115(16):2196–207.CrossRefPubMedGoogle Scholar
  86. 86.
    Berger JS, Bhatt DL, Cannon CP, Chen Z, Jiang L, Jones JB, et al. The relative efficacy and safety of clopidogrel in women and men a sex-specific collaborative meta-analysis. J Am Coll Cardiol. 2009;54(21):1935–45.CrossRefPubMedGoogle Scholar
  87. 87.
    Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–15.CrossRefPubMedGoogle Scholar
  88. 88.
    Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045–57.CrossRefPubMedGoogle Scholar
  89. 89.
    Husted S, James SK, Bach RG, Becker RC, Budaj A, Heras M, et al. The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J. 2014;35(23):1541–50.CrossRefPubMedCentralPubMedGoogle Scholar
  90. 90.
    Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012;366(15):1404–13.CrossRefPubMedGoogle Scholar
  91. 91.•
    Heran BS, Chen JM, Ebrahim S, Moxham T, Oldridge N, Rees K, Thompson DR, Taylor RS. Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst Rev. 2011;(7):Cd001800. This systematic review examines the effectiveness of exercise-based cardiac rehabilittion on mortality, morbidity, and health-related quality of life of patients with CHD.Google Scholar
  92. 92.
    Taylor RS, Brown A, Ebrahim S, Jolliffe J, Noorani H, Rees K, et al. Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. Am J Med. 2004;116(10):682–92.CrossRefPubMedGoogle Scholar
  93. 93.
    Jackson L, Leclerc J, Erskine Y, Linden W. Getting the most out of cardiac rehabilitation: a review of referral and adherence predictors. Heart. 2005;91(1):10–4.CrossRefPubMedCentralPubMedGoogle Scholar
  94. 94.
    Wenger NK, Speroff L, Packard B. Cardiovascular health and disease in women. N Engl J Med. 1993;329(4):247–56.CrossRefPubMedGoogle Scholar
  95. 95.
    Allen JK, Scott LB, Stewart KJ, Young DR. Disparities in women’s referral to and enrollment in outpatient cardiac rehabilitation. J Gen Intern Med. 2004;19(7):747–53.CrossRefPubMedCentralPubMedGoogle Scholar
  96. 96.
    Mosca L, Linfante AH, Benjamin EJ, Berra K, Hayes SN, Walsh BW, et al. National study of physician awareness and adherence to cardiovascular disease prevention guidelines. Circulation. 2005;111(4):499–510.CrossRefPubMedGoogle Scholar
  97. 97.
    Beckie TM, Beckstead JW. Predicting cardiac rehabilitation attendance in a gender-tailored randomized clinical trial. J Cardiopulm Rehabil Prev. 2010;30(3):147–56.CrossRefPubMedCentralPubMedGoogle Scholar
  98. 98.
    Beckie TM, Beckstead JW, Schocken DD, Evans ME, Fletcher GF. The effects of a tailored cardiac rehabilitation program on depressive symptoms in women: a randomized clinical trial. Int J Nurs Stud. 2011;48(1):3–12.CrossRefPubMedCentralPubMedGoogle Scholar
  99. 99.
    Grodstein F, Stampfer M. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog Cardiovasc Dis. 1995;38(3):199–210.CrossRefPubMedGoogle Scholar
  100. 100.
    Schierbeck LL, Rejnmark L, Tofteng CL, Stilgren L, Eiken P, Mosekilde L, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ (Clin Res Ed). 2012;345:e6409.Google Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.Department of MedicineBrigham and Women’s HospitalBostonUSA
  2. 2.Harvard Medical SchoolBostonUSA
  3. 3.Division of Cardiovascular MedicineBrigham and Women’s HospitalBostonUSA

Personalised recommendations